Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT02636075
Other study ID # 123456ab
Secondary ID
Status Enrolling by invitation
Phase N/A
First received December 5, 2015
Last updated December 18, 2015
Start date December 2015
Est. completion date February 2016

Study information

Verified date December 2015
Source SB Istanbul Education and Research Hospital
Contact n/a
Is FDA regulated No
Health authority Turkey: Ethics Committee
Study type Observational

Clinical Trial Summary

This study investigates if Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases or not.


Description:

Parathyroid tissues gets heavier when they become Hyperplasia. Because of this weight change, they change their normal anatomic positions. 125 patients who have been operated earlier will be included in the study.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 125
Est. completion date February 2016
Est. primary completion date January 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients who have undergone an operation due to parathyroid hyperplasia

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
SB Istanbul Education and Research Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Size of the thyroid tissue Longitudinal size (in mm) of each parathyroid tissue according to its anatomical location (upper, middle or lower 1/3 of the thyroid gland or below the thyroid) one year No
See also
  Status Clinical Trial Phase
Completed NCT03469310 - Minimizing Narcotic Analgesics After Endocrine Surgery Phase 4
Completed NCT04299425 - Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Completed NCT03027557 - Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Phase 3
Withdrawn NCT01421407 - Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism N/A